[18] Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. [19] Cocco E, Scaltriti M, Drilon A. NTRK fusion-pos...
Hexosaminidase B-driven cancer cell-macrophage co-dependency promotes glycolysis addiction and tumorigenesis in glioblastoma Reprogrammed metabolism drives cancer progression and is modulated by both cancer intrinsic variations and non-malignant cell populations in the tumor microenvironment. Here, the authors ...
[6] Li Z, Shen L, Ding D, et al. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(7):987-995. [7] D...
第二篇泛癌分析的文章于2022年同样发表在Nature Genetics(IF=30.8)上,题目为:Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment。当然啦,这篇文章我们公众号也进行过解读(影响因子40+的NG单细胞泛癌,真卷!!),并且在前些天Immungent大佬的泛癌思路梳理中...
其实文章也在附件里面提到:The non-cancer epithelial cell clusters (n = 16) were further annotated into cell subtypes (Figures S1D and S1E). 他们的数量如下所示: 一千七百多个 的正常的上皮细胞 可以看到正常水平细胞主要是 AT1和AT2 cells ,因为取材是肺部,因为取材跨越了不同治疗阶段(靶向治疗前(TN)...
首先是在Cell上发表了题为“Neutrophil profiling illuminates anti-tumor antigen-presenting potency”的研究论文,生成了覆盖17个癌种的中性粒细胞图谱(http://pancancer.cn/neu),探索了利用中性粒细胞抗原提呈来增敏免疫治疗。(吴...
2018-2022年5年期间,国内发表的大子刊论文(NBT、NCB、NG、NM、NI、NN、NSB、NMeth、NMicro、CCell、CSC、MC、CM、DC、Neuron、Immunity、STM)从185篇上升到260篇,然而2022年比2021年少5篇,考虑到新子刊NMeta、NBE、NAing、NCancer等国内文章发文量显著上升,子刊水平论文2022比2021还是增加的,但是增幅有限。再看...
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Cell. 2018 Apr 5;173(2):291-304.e6. 又比如 4 月 3 日 Cell Reports 的五连发: 1. 从DNA损伤修复角度分析基因组和分子图谱: Genomic and Molecular Landscape of DNA Damage Repair Deficiency ...
KEGG pathways significantly deregulated in Central Nervous System (CNS) disorders and Cancer types.Kristina IbáñezCesar BoullosaRafael TabarésSeisdedosAnaïs BaudotAlfonso Valencia
epithelial/cancer (EpCAM+,EPCAM), stromal (CD10+,MME,fibo or CD31+,PECAM1,endo) 这样挑出来的immune (CD45+,PTPRC),细胞亚群继续细分可以成为: B细胞,T细胞,巨噬细胞,树突细胞等等。不过这个时候的分群就没有那么死板的规则了,很多灵活调整的余地。